agilon health, inc. Stock 12‑Month Price Target Raised to $117.08, Implies 22% Upside

What happened

Analysts’ average 12-month price target for agilon health rose from $115.83 to $117.08, implying about 22% potential upside from the Nov. 4 closing price. Estimates from 12 analysts ranged from $85 to $146 per share; the overall rating remained Hold among 15 analysts.

Confirmed

Global impact / market context

The higher target signals that the analysts supplying estimates see slightly more potential value in agilon shares than before, but it does not change the overall Hold rating. Investors should distinguish a forecast from a company result: the article reports no change in revenue, costs, or cash available.

Analyst inference

The target increase is modest relative to the reported range of analyst estimates, while the 15-analyst consensus remains Hold. That mix indicates differing views: five analysts rate the stock Buy, nine Hold, and one Sell, so the average target is not a shared prediction.

Analyst inference

What to watch

1. Check whether future analyst updates move the $117.08 average target and whether estimates converge or remain spread between $85 and $146 per share. Analyst inference
2. Watch for changes in the consensus rating and the reported counts of Buy, Hold, and Sell recommendations, which could show whether analyst views are shifting. Analyst inference
3. Compare later target estimates with agilon’s reported business results; the article gives no operating figures, so it does not establish whether earnings or cash generation support the forecast. Analyst inference

Evidence

• Original source link unavailable